HLS Therapeutics Inc (TSE:HLS) has released an update.
A newly published study reveals that HLS Therapeutics Inc.’s pharmaceutical support programs significantly boost patient adherence to clozapine treatment, a crucial therapy for Treatment-Resistant Schizophrenia. The study, conducted using data from Quebec, Canada, shows a remarkable 69% persistence rate with HLS’s support program, compared to just 25% without such support, highlighting the potential for reduced healthcare costs and better patient outcomes. HLS is proud of the positive impact its Clozapine Support and Assistance Network (CSAN) has on patient care, as it leads to fewer hospital visits and a more stable treatment journey for patients.
For further insights into TSE:HLS stock, check out TipRanks’ Stock Analysis page.
